Stock Chart

DCTH

$14.51 +0.62%
Score: 61.2 HOLD
Pro
Screener
Vol: 0.78x (vs SPY: 1.0x | vs QQQ: 0.9x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 26, 2026
Bear Pennant weak / forming — below our quality gate quality 41/100
A Bear Pennant is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About DCTH - Delcath Systems Inc

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in …

Key Statistics

Market Cap $500M
P/E Ratio 1442.00

More DCTH Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This DCTH stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track DCTH's price movements with trendlines, gamma walls, and key support/resistance levels.